Suppr超能文献

患有血管性血友病及不同血管性血友病因子突变的女性的妊娠与分娩。

Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations.

机构信息

Department of Cell Therapy and Hematology, San Bortolo Hospital, I-36100 Vicenza, Italy.

出版信息

Haematologica. 2010 Jun;95(6):963-9. doi: 10.3324/haematol.2009.011239. Epub 2009 Nov 30.

Abstract

BACKGROUND

Pregnancy in von Willebrand's disease may carry a significant risk of bleeding. Information on changes in factor VIII and von Willebrand factor and pregnancy outcome in relation to von Willebrand factor gene mutations are very scanty.

DESIGN AND METHODS

We examined biological response to desmopressin, changes in factor VIII and von Willebrand factor and pregnancy outcome in a cohort of 23 women with von Willebrand's disease characterized at molecular level and prospectively followed during 2000-2007.

RESULTS

Thirty-one pregnancies occurred during the study period. Remarkably, similar changes of factor VIII and von Willebrand factor were observed after desmopressin and during pregnancy in nine women with R854Q, R1374H, V1665E, V1822G and C2362F mutations. Women with von Willebrand's disease and R1205H and C1130F mutations (17 pregnancies in 12 women) had only a slight increase of factor VIII and von Willebrand factor during pregnancy while their response to desmopressin was marked but short-lived. For these women, two to three desmopressin administrations within the first 48 hours were sufficient to successfully manage vaginal delivery. Two women with recessive von Willebrand's disease due to compound heterozygosity for different gene mutations had a spontaneous, major increase in factor VIII while von Willebrand factor remained severely reduced. Desmopressin increased factor VIII and was clinically useful in the first case, while a factor VIII/von Willebrand factor concentrate was required in the second patient not responsive to the compound. Factor VIII/von Willebrand factor concentrate was also required for two women with type 2 A von Willebrand's disease with V1665E mutations who had no von Willebrand factor activity change during pregnancy. In one of them, delayed bleeding occurred 15 days later requiring treatment with Factor VIII/von Willebrand factor concentrate. No miscarriages or stillbirths occurred.

CONCLUSIONS

Close follow-up and detailed guidelines for the management of parturition have produced a very low rate of immediate and late bleeding complications in this setting. Desmopressin was effective and safe in preventing significant bleeding at delivery in most of these patients.

摘要

背景

患有血管性血友病的孕妇可能有大出血的风险。关于因子 VIII 和血管性血友病因子的变化以及与血管性血友病因子基因突变相关的妊娠结局的信息非常有限。

设计与方法

我们在 2000 年至 2007 年期间,对 23 名血管性血友病患者进行了前瞻性研究,对这些患者的分子水平进行了特征描述,并检测了他们对去氨加压素的生物学反应、因子 VIII 和血管性血友病因子的变化以及妊娠结局。

结果

研究期间共发生 31 例妊娠。值得注意的是,在 9 名 R854Q、R1374H、V1665E、V1822G 和 C2362F 基因突变的患者中,去氨加压素和妊娠期间观察到因子 VIII 和血管性血友病因子的变化相似。12 名患者中的 17 例妊娠的 R1205H 和 C1130F 突变患者,因子 VIII 和血管性血友病因子在妊娠期间仅略有增加,而他们对去氨加压素的反应则明显但短暂。对于这些患者,在最初的 48 小时内给予 2 至 3 次去氨加压素治疗足以成功管理阴道分娩。2 名因不同基因突变复合杂合导致隐性血管性血友病的患者出现了因子 VIII 的自发性显著增加,而血管性血友病因子仍严重减少。去氨加压素增加了因子 VIII,在第一个病例中具有临床意义,而第二个对复合因素无反应的患者则需要因子 VIII/血管性血友病因子浓缩物。2 名患有 V1665E 突变的 2A 型血管性血友病患者在妊娠期间血管性血友病因子活性无变化,也需要因子 VIII/血管性血友病因子浓缩物。其中一名患者在 15 天后出现迟发性出血,需要使用因子 VIII/血管性血友病因子浓缩物治疗。没有发生流产或死胎。

结论

在这种情况下,密切随访和详细的分娩管理指南使即时和晚期出血并发症的发生率非常低。去氨加压素在预防大多数患者分娩时大出血方面是有效且安全的。

相似文献

引用本文的文献

1
von Willebrand disease and von Willebrand factor.血管性血友病和血管性血友病因子。
Haemophilia. 2022 May;28 Suppl 4(Suppl 4):11-17. doi: 10.1111/hae.14547.
8
von Willebrand disease.血管性血友病。
Genet Med. 2011 May;13(5):365-76. doi: 10.1097/GIM.0b013e3182035931.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验